Genomic Vision develops genetic screening tests for diagnostics and research. In the aftermath of the Myriad ruling, how can it use IP to develop market share? LSIPR spoke to chief executive Aaron Bensimon to find out.
When the Supreme Court decided earlier this year that isolated genetic material is not patent-eligible, it opened up the genetic screening market, inevitably introducing a new battleground for asserting IP rights on diagnostic technologies.
Many companies, including Ambry Genetics and Gene by Gene, started offering their own tests that could identify genetic disorders and susceptibility to certain diseases immediately after the June 13 ruling, and a series of patent infringement cases were filed among the companies soon after, as each tried to muscle in to the market.
French biotechnology company Genomic Vision offers a novel method of genome analysis. Its proprietary technology, which it calls molecular combing, allows researchers to view the genome at a high resolution and identify genetic anomalies within it.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Genomic Vision, IP strategy, genetic screening, Myriad, cancer